Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 3-arm, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ADS-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment

NCT03436199 is registered in ClinicalTrials.gov with Adamas Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03436199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03436199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 3-arm, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ADS-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment
Lead sponsor
Adamas Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 29, 2018
Completion date
December 10, 2019
Enrollment
558 (actual)
Sites
84

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, walking impairment